BioSpace News Archive

Alexo Therapeutics, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced it has initiated ALX148 combination dosing with targeted antibody therapies in its Phase 1 clinical program in patients with advanced solid tumors and lymphoma.

Precera Bioscience, Inc. (“Precera”), formerly Sano, appointed Pamela Weir as President and Chief Executive Officer effective January 1, 2018. Ms. Weir brings 30 years of pharmaceutical experience across diverse functions of Commercial, R&D, Operations, Business Development and General Management.

Company introduces new Board of Directors

Navitor Pharmaceuticals to Present at UBS Global Healthcare Conference

ConnectiveRx, a market-leader in patient and provider engagement services with hub, adherence and market access solutions for specialty and branded medications today announced the acquisition of The Macaluso Group (TMG), a technology-driven provider of specialty pharmacy benefits.

Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today provided a corporate update and announced financial results for the first quarter ended March 31, 2018.

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2018.

Medicure Inc. (“Medicure”) (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, will release financial results for the first quarter ended March 31, 2018 on Wednesday, May 23, 2018.

The U.S. Food and Drug Administration today approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults. The treatment is given by once-monthly self-injections. Aimovig is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule that is involved in migraine attacks.